首页> 外国专利> N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N, N'-(or n'n')alkylaminoalkyl ureas and cyanoguanidines

N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N, N'-(or n'n')alkylaminoalkyl ureas and cyanoguanidines

机译:N-(芳基-,芳氧基-,芳硫基-芳基亚磺酰基-和芳基磺酰基-)烷基-N,N'-(或n'n')烷基氨基烷基脲和氰基胍

摘要

Novel N-(Aryl-,aryloxy-,arylthio-,arylsulfinyl-and arylsulfonyl-)alkyl- N,N'-(or N',N')alkylaminoalkyl ureas, thioureas and cyanoguanidines represented by the following formula: ##STR1## wherein Ar is aryl selected from the group consisting of 1- and 2-naphthyl, 2,3- dihydro-1H- inden-4(or 5)-yl,2-furanylmethyl,2-pyridinyl, phenyl and phenyl substituted by 1-3 radicals commonly used in the pharmaceutical art; (X). sub.d is oxygen, thio, sulfinyl, sulfonyl or d is zero; Z and W are each R or-(CH.sub.2).sub.m -NR.sup.1 R.sup.2 wtih the proviso that when Z is R, W is-(CH.sub.2).sub.m -NR.sup.1 R.sup.2 and when Z is-(CH. sub.2).sub.m - NR.sup.1 R.sup.2, W is R; B is carbonyl, thioxomethyl, or cyanoiminomethyl; R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen, loweralkyl, cycloalkyl, phenyl or phenyl-loweralkyl wherein phenyl may be substituted by 1-3 radicals commonly used in the pharmaceutical art; R.sup.1 and R.sup.2, and R.sup.3 and R.sup.4 may together with the adjacent nitrogen form the heterocyclic ring structure 1-homopiperidinyl, 4-morpholinyl, 1-piperazinyl, 4- substituted-1-piperazinyl, 1-pyrrolidinyl or 1-piperidinyl and the pharmaceutically acceptable salts thereof are disclosed. A pharmaceutical method for administering the compounds for their cardiac antiarrhythmic effect and pharmaceutical compositions for the treatment of cardiac arrhythmia are also disclosed.
机译:新型N-(芳基-,芳氧基-,芳硫基-,芳基亚磺酰基-和芳基磺酰基-)烷基-N,N'-(或N',N')烷基氨基烷基脲,硫脲和氰基胍由下式表示:## STR1# #其中Ar是选自1-和2-萘基,2,3-二氢-1H-茚满-4(或5)-基,2-呋喃基甲基,2-吡啶基,苯基和被1取代的苯基的芳基-3在制药领域常用的自由基; (X)。 d是氧,硫代,亚磺酰基,磺酰基或d是零; Z和W各自为R或-(CH 2)m -NR s 1 R 2,条件是当Z为R时,W为-(CH 2)。 sub.m -NR.sup.1 R.sup.2,并且当Z是-(CH.sub.2)sub.m-NR.sup.1 R.sup.2时,W是R; B是羰基,硫代甲基或氰基氨基甲基; R,R 1,R 2,R 3和R 4选自氢,低级烷基,环烷基,苯基或苯基-低级烷基,其中苯基可以被1取代-3在制药领域常用的自由基; R 1和R 2,R 3和R 4可以与相邻的氮一起形成杂环结构1-同哌啶基,4-吗啉基,1-哌嗪基,4-取代的公开了-1-哌嗪基,1-吡咯烷基或1-哌啶基及其药学上可接受的盐。还公开了给予所述化合物用于其心脏抗心律不齐作用的药物方法和用于治疗心脏心律不齐的药物组合物。

著录项

  • 公开/公告号US4895840A

    专利类型

  • 公开/公告日1990-01-23

    原文格式PDF

  • 申请/专利权人 A. H. ROBINS COMPANY INCORPORATED;

    申请/专利号US19870060266

  • 发明设计人 JAMES R. SHANKLIN JR.;

    申请日1987-06-10

  • 分类号C07C127/17;C07C157/07;A61K31/17;

  • 国家 US

  • 入库时间 2022-08-22 06:08:00

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号